Aaron “Ron” Weitzman, M.D., FACP, oversees development operations as the Chief Medical Officer of Tango Therapeutics. Over his 20+ years in the biopharmaceutical industry, Ron has been involved in advancing small molecules, cytotoxic agents, and monoclonal antibodies at all stages of clinical development.
Dr. Weitzman has served as Vice President of Clinical Development at Exelixis, where he oversaw the global development of CABOMETYX®. He also had senior clinical positions at Genentech, Novartis, and Eli Lilly and Company, where he played key roles in the development of AVASTIN® and TASIGNA®. Dr. Weitzman obtained his M.D. from the Medical School at the University of Western Ontario, Canada. He completed his medical residency at Mount Sinai Medical Center and completed his clinical fellowship in Medical Oncology at Columbia-Presbyterian Medical Center in New York City.